



\$1653  
RECEIVED

SFP 24 2002

TECH CENTER 1600/2900

PATENT APPLICATION

File No: 97-44D1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of : David A. Adler, James L. Holloway, Nand Baindur, Stephanie Beigel-  
Orme, Paul O. Sheppard  
Serial No. : 10/091,166  
Group Art Unit : 1653  
Examiner :  
Filed : March 5, 2002  
For : NOVEL BETA-DEFENSINS

**CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Information Disclosure Statement (in duplicate)
2. PTO-1449 Form
3. 48 References
4. Return Postcard

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on September 16, 2002.

  
\_\_\_\_\_  
Lara Russell

**Information Disclosure Statement**

Page 2 of 2

Applicant(s): Adler et al.

Serial No.: 10/091,166


Filed: March 5, 2002

For: NOVEL BETA-DEFENSINS

---

Since this Information Disclosure Statement is submitted after receipt of an Office Action in the above-identified patent application, please charge a fee of \$180 to Deposit Account No. 26-0290 under 37 C.F.R. §§1.97(d) and 1.17(p). Please charge any additional fees or credit any overpayment to Deposit Account No. 26-0290.

Respectfully submitted,



Brian J. Walsh

Registration No. 45,543

Direct Dial - (206) 442-6540



PATENT APPLICATION  
File No: 97-44D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : David A. Adler, James L. Holloway, Nand Baindur, Stephanie  
Beigel-Orme, Paul O. Sheppard  
Serial No. : 10/091,166,  
Group Art Unit : 1653  
Examiner :  
Filed : March 5, 2002  
For : NOVEL BETA-DEFENSINS  
Date Submitted : September 16, 2002

RECEIVED

SEP 24 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, DC 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. §1.56, and in accordance with C.F.R. §§1.97 *et. seq.*, references listed on the enclosed 1449 form(s) are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents listed on the attached 1449 form(s) is respectfully requested.

The present application is a divisional of U.S. Patent Application Serial No. 09/636,399, filed August 10, 2000, which is a continuation-in-part of U.S. Patent Application Serial No. 09/344,097, filed June 25, 1999, which is a continuation-in-part of U.S. Patent Application Serial No. 09/150,786, filed September 10, 1998, which claims the benefit of U.S. Patent Application Serial No. 60/064,294, filed November 5, 1997, and U.S. Patent Application Serial No. 60/058,335, filed September 10, 1997.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

09/23/2002 SSESHE1 00000088 260290 10091166

01 FC:126 180.00 CH

SEP 20 2002

SEP 24 2002

TECH CENTER 1609/2000 1 of 6

FORM 1449  
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. Sheppard

Filing Date:  
March 5, 2002

Group: 1653

U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL |  | DOCUMENT<br>NUMBER | DATE | Name | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--|--------------------|------|------|-------|----------|-------------------------------|
|                     |  |                    |      |      |       |          |                               |
|                     |  |                    |      |      |       |          |                               |
|                     |  |                    |      |      |       |          |                               |
|                     |  |                    |      |      |       |          |                               |

FOREIGN PATENT DOCUMENTS

| Examiner<br>Initial |    | DOCUMENT<br>NUMBER | Date     | COUNTRY | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|----|--------------------|----------|---------|-------|----------|-------------------------------|
|                     | A1 | 95/32287           | 11/30/95 | PCT     |       |          |                               |
|                     | A2 | 99/06554           | 02/11/99 | PCT     |       |          |                               |
|                     | A3 | 00/07612           | 02/17/00 | PCT     |       |          |                               |
|                     | A4 | 00/46245           | 08/10/00 | PCT     |       |          |                               |
|                     | A5 | 01/42467           | 06/14/00 | PCT     |       |          |                               |
|                     | A6 | 02/04487           | 01/17/02 | PCT     |       |          |                               |
|                     | A7 | 02/40512           | 05/23/02 | PCT     |       |          |                               |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

|  |     |  |   |
|--|-----|--|---|
|  | A8  |  | Jia et al., "Discovery of new human beta-defensins using a genomics-based approach," <u>Gene</u> , 263(1-2):211-218 (Jan. 2001).          |
|  | A9  |  | Lehrer et al. "Defensins: antimicrobial and cytotoxic peptides of mammalian cells," <u>Annu Rev Immunol.</u> , 11:105-128 (1993). Review. |
|  | A10 |  | Harder et al. "A peptide antibiotic from human skin," <u>Nature</u> , 387(6636):861 (June 26, 1997).                                      |
|  | A11 |  | Incyte Pharmaceuticals, Inc. clone, 1996:INC1433022.  |
|  | A12 |  | Incyte Pharmaceuticals, Inc. LIBRARY, 1996:BEPINON01.   |

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 20 2002

Sheet 2 of 6

FORM PTO 1449  
(REV 2-32)

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. Sheppard

Filing Date:  
March 5, 2002

Group: 1653

U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER | DATE | Name | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|------|-------|----------|-------------------------------|
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |

RECEIVED  
SEP 24 2002

FOREIGN PATENT DOCUMENTS

| Examiner<br>Initial | DOCUMENT<br>NUMBER | Date | COUNTRY | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|---------|-------|----------|-------------------------------|
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |

TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

|  |     |  |  |
|--|-----|--|--|
|  | A13 |  | Incyte Pharmaceuticals, Inc. LIBRARY, 1996: LPARNOT02.   |
|  | A14 |  | Selsted et al., "Purification, primary structures, and antibacterial activities of beta-defensins, a new family of antimicrobial peptides from bovine neutrophils," <u>J Biol Chem.</u> , 268(9):6641-6648 (March 25, 1993). |
|  | A15 |  | Bensch et al., "hBD-1: a novel beta-defensin from human plasma," <u>FEBS Lett.</u> , 368(2):331-335 (July 17, 1995).   |
|  | A16 |  | Bowie et al., "Deciphering the message in protein sequences: tolerance to amino acid substitutions," <u>Science</u> , 247(4948):1306-1310 (March 16, 1990).  |
|  | A17 |  | Wells, J.A., "Additivity of mutational effects in proteins," <u>Biochemistry</u> , 29(37):8509-8517 (Sept. 18, 1990).  |
|  | A18 |  | Liu et al., "Structure and mapping of the human beta-defensin HBD-2 gene and its expression at sites of inflammation," <u>Gene</u> , 222(2):237-244 (Nov. 19, 1998).   |
|  | A19 |  | Porter et al., "Broad-spectrum antimicrobial activity of human intestinal defensin 5," <u>Infect Immun.</u> , 65(6):2396-2401 (June 1997).   |
|  | A20 |  | Daher et al., "Direct inactivation of viruses by human granulocyte defensins," <u>J Virol.</u> , 60(3):1068-1074 (Dec. 1986).  |

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEP 20 2002

Sheet 3 of 6

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. SheppardFiling Date:  
March 5, 2002

Group: 1653

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER | DATE | Name | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|------|-------|----------|-------------------------------|
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |

## FOREIGN PATENT DOCUMENTS

| Examiner<br>Initial | DOCUMENT<br>NUMBER | Date | COUNTRY | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|---------|-------|----------|-------------------------------|
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

|  |     |  |   |
|--|-----|--|---|
|  | A21 |  | Martin et al., "Defensins and other endogenous peptide antibiotics of vertebrates," <u>J Leukoc Biol.</u> , 58(2):128-136 (Aug. 1995). Review.  |
|  | A22 |  | Ouellette et al., "Paneth cell defensins: endogenous peptide components of intestinal host defense," <u>FASEB J.</u> , 10(11):1280-1289 (Sept. 1996). Review.                                   |
|  | A23 |  | Lichtenstein et al., "In vitro tumor cell cytolysis mediated by peptide defensins of human and rabbit granulocytes," <u>Blood</u> , 68(6):1407-1410 (Dec. 1986).                                |
|  | A24 |  | Zhu et al., "Isolation and structure of corticostatin peptides from rabbit fetal and adult lung," <u>Proc Natl Acad Sci U S A.</u> , 85(2):592-596 (Jan. 1988).                                 |
|  | A25 |  | Territo et al., "Monocyte-chemotactic activity of defensins from human neutrophils," <u>J Clin Invest.</u> , 84(6):2017-2020 (Dec. 1989).   |
|  | A26 |  | Tamura et al., "A marked decrease in defensin mRNA in the only case of congenital neutrophil-specific granule deficiency reported in Japan," <u>Int J Hematol.</u> , 59(2):137-142 (Feb. 1994). |
|  | A27 |  | Higazi et al., "Defensin modulates tissue-type plasminogen activator and plasminogen binding to fibrin and endothelial cells," <u>J Biol Chem.</u> , 271(30):17650-5 (July 26, 1996).           |
|  | A28 |  | Yang et al., "Mammalian defensins in immunity: more than just microbicidal," <u>Trends Immunol.</u> , 23(6):291-6 (June 2002).  |

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SEP 20 2002

SEP 24 2002

TECH CENTER 1600/2900  
Sheet 1 of 6FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. SheppardFiling Date:  
March 5, 2002

Group: 1653

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER | DATE | Name | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|------|-------|----------|-------------------------------|
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |

## FOREIGN PATENT DOCUMENTS

| Examiner<br>Initial | DOCUMENT<br>NUMBER | Date | COUNTRY | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|---------|-------|----------|-------------------------------|
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

|  |     |  |  |
|--|-----|--|--|
|  | A29 |  | Circo et al., "Structural and functional characterization of hBD-1(Ser35), a peptide deduced from a DEFB1 polymorphism," <u>Biochem Biophys Res Commun.</u> , 293(1):586-92 (April 26, 2002).  |
|  | A30 |  | Schibli et al., "The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus," <u>J Biol Chem.</u> , 277(10):8279-89 (March 8, 2002). |
|  | A31 |  | Harder et al., "Isolation and characterization of human beta -defensin-3, a novel human inducible peptide antibiotic," <u>J Biol Chem.</u> , 276(8):5707-13 (Feb. 23, 2001).   |
|  | A32 |  | Goldman et al., "Human beta-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis," <u>Cell</u> , 88(4):553-60 (Feb. 21, 1997).   |
|  | A33 |  | Smith et al., "Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid," <u>Cell</u> , 85(2):229-36 (April 19, 1996).  |
|  | A34 |  | Davies et al., "CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium," <u>Am J Respir Cell Mol Biol.</u> , 16(6):657-63 (June 1997).   |
|  | A35 |  | Dunsche et al., "The novel human beta-defensin-3 is widely expressed in oral tissues," <u>Eur. J. Oral. Sci.</u> , 109:121-124 (2002).   |

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



SEP 24 2002

TECH CENTER 1600/2900  
Sheet 5 of 8FORM 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. SheppardFiling Date:  
March 5, 2002

Group: 1653

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER | DATE | Name | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|------|-------|----------|-------------------------------|
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |

## FOREIGN PATENT DOCUMENTS

| Examiner<br>Initial | DOCUMENT<br>NUMBER | Date | COUNTRY | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|---------|-------|----------|-------------------------------|
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)


|  |     |   |
|--|-----|---|
|  | A36 | Cullor et al., "In vitro antimicrobial activity of defensins against ocular pathogens," <u>Arch Ophthalmol.</u> , 108(6):861-864 (June 1990).   |
|  | A37 | Schwab et al., "Corneal storage medium preservation with defensins," <u>Cornea</u> , 11(5):370-375 (Sept. 1992).  |
|  | A38 | Yeh et al., "Single-dose pharmacokinetics of indinavir and the effect of food," <u>Antimicrob Agents Chemother.</u> , 42(2):332-338 (Feb. 1998).  |
|  | A39 | Haynes et al., "Innate defence of the eye by antimicrobial defensin peptides," <u>Lancet</u> , 352(9126):451-452 (Aug. 8, 1998).  |
|  | A40 | Haynes et al., "Antimicrobial defensin peptides of the human ocular surface," <u>Br J Ophthalmol.</u> , 83(6):737-41 (June 1999).   |
|  | A41 | Sawicki et al., "Contraceptive potential of peptide antibiotics," <u>Lancet</u> , 353(9151):464-5 (Feb. 6, 1999).   |
|  | A42 | Garcia et al., "Identification of a novel, multifunctional beta-defensin (human beta-defensin 3) with specific antimicrobial activity. Its interaction with plasma membranes of <i>Xenopus</i> oocytes and the induction of macrophage chemoattraction," <u>Cell Tissue Res.</u> , 306(2):257-64 (Nov. 2001). |
|  |     |   |
|  |     |   |

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





SEP 24 2002

TECH CENTER 1609/2900 6 of 6

FORM PTO 1449  
(REV 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

File No. 97-44D1

Serial No.  
10/091,166

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant(s):  
David A. Adler, James L. Holloway,  
Nand Baindur, Stephanie Beigel-Orme,  
Paul O. SheppardFiling Date:  
March 5, 2002

Group: 1653

## U.S. PATENT DOCUMENTS

| EXAMINER<br>INITIAL | DOCUMENT<br>NUMBER | DATE | Name | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|------|-------|----------|-------------------------------|
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |
|                     |                    |      |      |       |          |                               |

## FOREIGN PATENT DOCUMENTS

| Examiner<br>Initial | DOCUMENT<br>NUMBER | Date | COUNTRY | CLASS | SUBCLASS | FILING DATE IF<br>APPROPRIATE |
|---------------------|--------------------|------|---------|-------|----------|-------------------------------|
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |
|                     |                    |      |         |       |          |                               |

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

|  |     |  |   |
|--|-----|--|---|
|  | A43 |  | Zasloff, M., "Antimicrobial peptides of multicellular organisms," <u>Nature</u> , 415:389-395 (Jan. 2002).  |
|  | A44 |  | Krisanaprakornkit et al., "Regulation of human beta-defensin-2 in gingival epithelial cells: the involvement of mitogen-activated protein kinase pathways, but not the NF-kappaB transcription factor family," <u>J Immunol.</u> , 168(1):316-324 (Jan. 1, 2002). |
|  | A45 |  | Garcia et al., "Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity," <u>FASEB J.</u> , express article 10.1096/fj.00-0865fje, published online on June 18, 2001.                                  |
|  | A46 |  | Duits et al., "Inhibition of hBD-3, but not hBD-1 and hBD-2, mRNA expression by corticosteroids," <u>Biochem Biophys Res Commun.</u> , 280(2):522-525 (Jan. 2001).  |
|  | A47 |  | Hancock et al., "Antibiotic resistance in <i>Pseudomonas aeruginosa</i> : mechanisms and impact on treatment," <u>Drug Resist Updat.</u> , 3(4):247-255 (Aug. 2000).  |
|  | A48 |  | Biragyn et al., "DNA vaccines encoding human immunodeficiency virus-1 glycoprotein 120 fusions with proinflammatory chemoattractants induce systemic and mucosal immune responses," <u>Blood</u> , 100(4):1153-1159 (Aug. 15, 2002).                              |
|  |     |  |   |
|  |     |  |   |

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.